Navigation Links
Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million
Date:2/20/2009

embership interest in the joint venture to Spectrum, CTI will receive $6 million, with the remainder of the $18 million to be paid within 90 days following such closing. The closing of the sale option transaction is contingent upon the satisfaction of certain closing conditions, including the delivery of a legal opinion from counsel to CTI, as specified in the operating agreement for the Zevalin joint venture. CTI believes that it will be in a position to promptly satisfy all of the closing conditions.

About Zevalin(R)

Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, lowgrade or follicular B-cell non-Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. Zevalin is also indicated, under accelerated approval, for the treatment of relapsed or refractory, rituximab-naive, low-grade and follicular NHL based on studies using a surrogate endpoint of overall response rate. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab (Rituxan(R)) infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). Zevalin should only be use
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015  Quest Diagnostics Incorporated ... diagnostic information services, announced that it is scheduled to ... New York.  Steve Rusckowski , the company,s President ... five point strategy.  The presentation is scheduled for Tuesday, ... The presentation will be webcast live during the ...
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/26qndf/nanobiotechnology ) ... new report "Nanobiotechnology Applications, Markets and ... An increasing use of nanobiotechnology by the ... will be applied at all stages of ... delivery to diagnostic applications in clinical trials. ...
(Date:5/28/2015)... May 27, 2015 Research and Markets( ... PharmaBiotech,s new report "Cell Therapy - Technologies, ... This report describes and evaluates cell therapy ... play an important role in the practice of ... old fashioned bone marrow transplants. Role of cells ...
(Date:5/28/2015)... Muncie, IN (PRWEB) May 28, 2015 The ... annual National Model Aviation Day on August 15, 2015. National ... model aviation nation-wide and to introduce model flying to the ... approximately 2,350 chartered clubs to participate in the celebration by ... have registered to host National Model Aviation Day events. ...
Breaking Biology Technology:Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 3Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2Model flying pilots celebrate the Academy of Model Aeronautics Foundation’s Third Annual National Model Aviation Day 2
... FDA Submission for Removal of Clinical Hold, ... Bulletin Board: GNTA) announced that the Company has,received ... the European,Patent Office for its pipeline product, tesetaxel, ... of matter for the tesetaxel drug,substance and to ...
... Technology to Lexicon Targets, COPENHAGEN, June 10 ... Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ) aimed,at ... for highly,validated drug targets., Under the terms ... will be applied to identify novel small molecule,lead ...
... Mass., June 9 Boston Scientific,Corporation (NYSE: ... Ratings,that it has revised its Rating Outlook on ... the Company,s long-term credit rating of,BB+., Fitch ... progress Boston,Scientific is making toward stabilizing its drug-eluting ...
Cached Biology Technology:Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane 2Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane 3Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane 4Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals 2Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals 3Boston Scientific Welcomes Revised Outlook From Fitch Ratings 2Boston Scientific Welcomes Revised Outlook From Fitch Ratings 3
(Date:5/8/2015)... Calif. , May 8, 2015 Synaptics Inc. ... solutions, today announced that members of the executive management team ... Morgan 43rd Annual Technology, Media and Telecom Conference Date: ... Hotel in Boston, MA ... 27, 2015 Time: 2:45pm ET Location: The New York Palace ...
(Date:4/27/2015)... , Apr. 27, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... shipping to pre-order customers the first week of May, ... the month of May. Gino ... significant milestone for the company as Wocket® enters the ...
(Date:4/17/2015)... BURNABY, Canada , April 17, 2015 /PRNewswire/ ... projects, growing security concerns, and technological advancement to ... Arabia until 2020   ... " Saudi Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric ... is projected to register growth at CAGR ...
Breaking Biology News(10 mins):Synaptics to Present at Upcoming Investor Conferences 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... - With infections increasingly resistant to even the most ... Institute at Harbor-UCLA Medical Center (LA BioMed) report in ... clues they have uncovered in immune system molecules that ... Nannette Y. Yount present evidence that small proteins in ...
... prove a permanent turn on for some genes. Research published today ... why former smokers are still more susceptible to lung cancer than ... by Wan L Lam and Stephen Lam from the BC Cancer ... smokers, as well as from non-smokers who have never smoked. They ...
... AK The historic collaboration between leading scientists and ... for Health and the ,Global Environment at Harvard Medical ... continues this week with a trip to Alaska. A ... traveling together on August 25th to observe first- ,hand ...
Cached Biology News:Researchers discover new strategies for antibiotic resistance 2Smoking turns on genes -- permanently 2Scientist-evangelical Alaska expedition 2
...
... 48° Fixed Angle Polypropylene Rotor designed ... IEC Centra CL3/CL3R** and Centra-MP4/MP4R*. A ... operation. /MP4, ,EXCLUSIVE polypropylene rotor design ... be repeatedly autoclaved. Polypropylene rotors ...
... The Xcise is a powerful technology platform ... proteome analysis. High quality sample preparation ... user. , The Xcise is a powerful ... high throughput proteome analysis. It combines the ...
Request Info...
Biology Products: